Sangamo Therapeutics
SGMO
SGMO
130 hedge funds and large institutions have $47.7M invested in Sangamo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
22% less capital invested
Capital invested by funds: $61.3M → $47.7M (-$13.7M)
38% less call options, than puts
Call options by funds: $45K | Put options by funds: $72K
Holders
130
Holding in Top 10
–
Calls
$45K
Puts
$72K
Top Buyers
| 1 | +$1.18M | |
| 2 | +$990K | |
| 3 | +$694K | |
| 4 |
Two Sigma Advisers
New York
|
+$675K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$653K |
Top Sellers
| 1 | -$3.94M | |
| 2 | -$3.04M | |
| 3 | -$2.22M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.79M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$1.13M |